Effect of probiotic administration on the intestinal microbiota, current knowledge and potential applications

World Journal of Gastroenterology

Volumn 20, Issue 44, 2014, Pages 16518-16528

  De LeBlanc, Alejra Moreno De ^a   LeBlanc, Jean Guy ^a  

^a CENTRO DE REFERENCIA PARA LACTOBACILOS CERELA CONICET   (Argentina)

Author keywords

Dysbiosis; Gut microbiota; Probiotics; Symbiosis; Treatment

Indexed keywords

PROBIOTIC AGENT;

ARTICLE; DRUG EFFICACY; ENTEROPATHY; FECAL MICROBIAL TRANSPLANTATION; HOST; HUMAN; INTESTINE FLORA; INTESTINE TRANSPLANTATION; NONHUMAN; RANDOMIZED CONTROLLED TRIAL (TOPIC); ANIMAL; BIOLOGICAL THERAPY; FECES; INTESTINAL DISEASES; INTESTINE; MICROBIOLOGY; MICROFLORA; TREATMENT OUTCOME;

ANIMALS; BIOLOGICAL THERAPY; FECES; HUMANS; INTESTINAL DISEASES; INTESTINES; MICROBIOTA; PROBIOTICS; TREATMENT OUTCOME;

EID: 84918799890     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i44.16518     Document Type: Article

References (74)

1. Food and Agriculture Organization/World Health Organization. Joint FAO/WHO expert consultation on evaluation of health and nutritional properties of probiotics in food in-cluding powder milk with live lactic acid bacteria. Cordoba, Argentina, 1 to 4 October 2001. Available from: URL: http:// www.who.int/foodsafety/publications/fs-management/en/probiotics.pdf
2. Bäckhed F, Ley RE, Sonnenburg JL, Peterson DA, Gordon JI. Host-bacterial mutualism in the human intestine. Science 2005; 307: 1915-1920 [PMID: 15790844 DOI: 10.1126/sci-ence.1104816]
3. Ley RE, Peterson DA, Gordon JI. Ecological and evolutionary forces shaping microbial diversity in the human intestine. Cell 2006; 124: 837-848 [PMID: 16497592 DOI: 10.1016/ j.cell.2006.02.017]
4. Turnbaugh PJ, Ley RE, Hamady M, Fraser-Liggett CM, Knight R, Gordon JI. The human microbiome project. Nature 2007; 449: 804-810 [PMID: 17943116 DOI: 10.1038/nature06244]
5. Zilber-Rosenberg I, Rosenberg E. Role of microorganisms in the evolution of animals and plants: the hologenome theory of evolution. FEMS Microbiol Rev 2008; 32: 723-735 [PMID: 18549407 DOI: 10.1111/j.1574-6976.2008.00123.x]
6. Fujimura KE, Slusher NA, Cabana MD, Lynch SV. Role of the gut microbiota in defining human health. Expert Rev Anti Infect Ther 2010; 8: 435-454 [PMID: 20377338 DOI: 10.1586/ eri.10.14]
7. Bakhtiar SM, LeBlanc JG, Salvucci E, Ali A, Martin R, Langella P, Chatel JM, Miyoshi A, Bermúdez-Humarán LG, Azevedo V. Implications of the human microbiome in inflammatory bowel diseases. FEMS Microbiol Lett 2013; 342: 10-17 [PMID: 23431991 DOI: 10.1111/1574-6968.12111]
8. Chan YK, Estaki M, Gibson DL. Clinical consequences of diet-induced dysbiosis. Ann Nutr Metab 2013; 63 Suppl 2: 28-40 [PMID: 24217034 DOI: 10.1159/000354902]
9. Vipperla K, O'Keefe SJ. The microbiota and its metabolites in colonic mucosal health and cancer risk. Nutr Clin Pract 2012; 27: 624-635 [PMID: 22868282 DOI: 10.1177/0884533612 452012]
10. Ashraf R, Shah NP. Immune system stimulation by probiotic microorganisms. Crit Rev Food Sci Nutr 2014; 54: 938-956 [PMID: 24499072 DOI: 10.1080/10408398.2011.619671]
11. Matricon J, Barnich N, Ardid D. Immunopathogenesis of inflammatory bowel disease. Self Nonself 2010; 1: 299-309 [PMID: 21487504]
12. Koboziev I, Reinoso Webb C, Furr KL, Grisham MB. Role of the enteric microbiota in intestinal homeostasis and inflammation. Free Radic Biol Med 2014; 68: 122-133 [PMID: 24275541 DOI: 10.1016/j.freeradbiomed.2013.11.008]
13. Fava F, Danese S. Intestinal microbiota in inflammatory bowel disease: friend of foe? World J Gastroenterol 2011; 17: 557-566 [PMID: 21350704 DOI: 10.3748/wjg.v17.i5.557]
14. Takaishi H, Matsuki T, Nakazawa A, Takada T, Kado S, Asahara T, Kamada N, Sakuraba A, Yajima T, Higuchi H, Inoue N, Ogata H, Iwao Y, Nomoto K, Tanaka R, Hibi T. Imbalance in intestinal microflora constitution could be involved in the pathogenesis of inflammatory bowel disease. Int J Med Microbiol 2008; 298: 463-472 [PMID: 17897884 DOI: 10.1016/j.ijmm.2007.07.016]
15. Weir TL, Manter DK, Sheflin AM, Barnett BA, Heuberger AL, Ryan EP. Stool microbiome and metabolome differences between colorectal cancer patients and healthy adults. PLoS One 2013; 8: e70803 [PMID: 23940645 DOI: 10.1371/journal. pone.0070803]
16. Hamer HM, Jonkers D, Venema K, Vanhoutvin S, Troost FJ, Brummer RJ. Review article: the role of butyrate on colonic function. Aliment Pharmacol Ther 2008; 27: 104-119 [PMID: 17973645]
17. Zhu Q, Jin Z, Wu W, Gao R, Guo B, Gao Z, Yang Y, Qin H. Analysis of the intestinal lumen microbiota in an animal model of colorectal cancer. PLoS One 2014; 9: e90849 [PMID: 24603888 DOI: 10.1371/journal.pone.0090849]
18. Huipeng W, Lif eng G, Chuang G, Jiaying Z, Yuankun C. The differences in colonic mucosal microbiota between normal individual and colon cancer patients by polymerase chain reaction-denaturing gradient gel electrophoresis. J Clin Gastroenterol 2014; 48: 138-144 [PMID: 24162169 DOI: 10.1097/ MCG.0b013e3182a26719]
19. Song X, Gao H, Lin Y, Yao Y, Zhu S, Wang J, Liu Y, Yao X, Meng G, Shen N, Shi Y, Iwakura Y, Qian Y. Alterations in the microbiota drive interleukin-17C production from intestinal epithelial cells to promote tumorigenesis. Immunity 2014; 40: 140-152 [PMID: 24412611 DOI: 10.1016/j.immuni.2013.11.018]
20. Ling Z, Li Z, Liu X, Cheng Y, Luo Y, Tong X, Yuan L, Wang Y, Sun J, Li L, Xiang C. Altered fecal microbiota composition associated with food allergy in infants. Appl Environ Microbiol 2014; 80: 2546-2554 [PMID: 24532064 DOI: 10.1128/ aem.00003-14]
21. Fallucca F, Porrata C, Fallucca S, Pianesi M. Influence of diet on gut microbiota, inflammation and type 2 diabetes mellitus. First experience with macrobiotic Ma-Pi 2 diet. Diabetes Metab Res Rev 2014; 30 Suppl 1: 48-54 [PMID: 24532292 DOI: 10.1002/dmrr.2518]
22. Qin J, Li Y, Cai Z, Li S, Zhu J, Zhang F, Liang S, Zhang W, Guan Y, Shen D, Peng Y, Zhang D, Jie Z, Wu W, Qin Y, Xue W, Li J, Han L, Lu D, Wu P, Dai Y, Sun X, Li Z, Tang A, Zhong S, Li X, Chen W, Xu R, Wang M, Feng Q, Gong M, Yu J, Zhang Y, Zhang M, Hansen T, Sanchez G, Raes J, Falony G, Oku da S, Almeida M, LeChatelier E, Renault P, Pons N, Batto JM, Zhang Z, Chen H, Yang R, Zheng W, Li S, Yang H, Wang J, Ehrlich SD, Nielsen R, Pedersen O, Kristiansen K, Wang J. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature 2012; 490: 55-60 [PMID: 23023125 DOI: 10.1038/nature11450]
23. Riley LW, Raphael E, Faerstein E. Obesity in the United States - dysbiosis from exposure to low-dose antibiotics? Front Public Health 2013; 1: 69 [PMID: 24392444 DOI: 10.3389/ fpubh.2013.00069]
24. Kaplan JL, Walker WA. Early gut colonization and subsequent obesity risk. Curr Opin Clin Nutr Metab Care 2012; 15: 278-284 [PMID: 22327336 DOI: 10.1097/MCO.0b013e32835133cb]
25. Cani PD, Osto M, Geurts L, Everard A. Involvement of gut microbiota in the development of low-grade inflammation and type 2 diabetes associated with obesity. Gut Microbes 2012; 3: 279-288 [PMID: 22572877 DOI: 10.4161/gmic.19625]
26. Harris K, Kassis A, Major G, Chou CJ. Is the gut microbiota a new factor contributing to obesity and its metabolic disorders? J Obes 2012; 2012: 879151 [PMID: 22315672 DOI: 10.1155/2012/879151]
27. Shen J, Obin MS, Zhao L. The gut microbiota, obesity and insulin resistance. Mol Aspects Med 2013; 34: 39-58 [PMID: 23159341 DOI: 10.1016/j.mam.2012.11.001]
28. Bäckhed F, Ding H, Wang T, Hooper LV, Koh GY, Nagy A, Semenkovich CF, Gordon JI. The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci USA 2004; 101: 15718-15723 [PMID: 15505215 DOI: 10.1073/ pnas.0407076101]
29. S calera A, Di Minno MN, Tarantino G. What does irritable bowel syndrome share with non-alcoholic fatty liver disease? World J Gastroenterol 2013; 19: 5402-5420 [PMID: 24023483 DOI: 10.3748/wjg.v19.i33.5402]
30. Peniche AG, Savidge TC, Dann SM. Recent insights into Clostridium difficile pathogenesis. Curr Opin Infect Dis 2013; 26: 447-453 [PMID: 23982235 DOI: 10.1097/01.qco.0000433318.82618. c6]
31. Antharam VC, Li EC, Ishmael A, Sharma A, Mai V, Rand KH, Wang GP. Intestinal dysbiosis and depletion of butyrogenic bacteria in Clostridium difficile infection and nosocomial diarrhea. J Clin Microbiol 2013; 51: 2884-2892 [PMID: 23804381 DOI: 10.1128/jcm.00845-13]
32. Di Bella S, Drapeau C, Garcia-Almodovar E, Petrosillo N. Fecal microbiota transplantation: the state of the art. Infect Dis Rep 2013; 5: e!3 [PMID: 24470963 DOI: 10.4081/idr.2013. e13]
33. Pamer EG. Fecal microbiota transplantation: effectiveness, complexities, and lingering concerns. Mucosal Immunol 2014; 7: 210-214 [PMID: 24399149 DOI: 10.1038/mi.2013.117]
34. Dutta SK, Girotra M, Garg S, Dutta A, von Rosenvinge EC, Maddox C, Song Y, Bartlett JG, Vinayek R, Fricke WF. Efficacy of combined jejunal and colonic fecal microbiota transplantation for recurrent Clostridium difficile Infection. Clin Gastroenterol Hepatol 2014; 12: 1572-1576 [PMID: 24440222 DOI: 10.1016/j.cgh.2013.12.032]
35. Weingarden AR, Chen C, Bobr A, Yao D, Lu Y, Nelson VM, Sadowsky MJ, Khoruts A. Microbiota transplantation restores normal fecal bile acid composition in recurrent Clostridium difficile infection. Am J Physiol Gastrointest Liver Physiol 2014; 306: G310-G319 [PMID: 24284963 DOI: 10.1152/ ajpgi.00282.2013]
36. Smits LP, Bouter KE, de Vos WM, Borody TJ, Nieuwdorp M. Therapeutic potential of fecal microbiota transplantation. Gastroenterology 2013; 145: 946-953 [PMID: 24018052 DOI: 10.1053/j.gastro.2013.08.058]
37. Damman CJ, Miller SI, Surawicz CM, Zisman TL. The microbiome and inflammatory bowel disease: is there a therapeutic role for fecal microbiota transplantation? Am J Gastroenterol 2012; 107: 1452-1459 [PMID: 23034604 DOI: 10.1038/ajg.2012.93]
38. Kunde S, Pham A, Bonczyk S, Crumb T, Duba M, Conrad H, Cloney D, Kugathasan S. Safety, tolerability, and clinical response after fecal transplantation in children and young adults with ulcerative colitis. J Pediatr Gastroenterol Nutr 2013; 56: 597-601 [PMID: 23542823 DOI: 10.1097/ MPG.0b013e318292fa0d]
39. De Leon LM, Watson JB, Kelly CR. Transient flare of ulcerative colitis after fecal microbiota transplantation for recurrent Clostridium difficile infection. Clin Gastroenterol Hepatol 2013; 11:1036-1038 [PMID: 23669309 DOI: 10.1016/j.cgh.2013.04.045]
40. Angelberger S, Reinisch W, Makristathis A, Lichtenberger C, Dejaco C, Papay P, Novacek G, Trauner M, Loy A, Berry D. Temporal bacterial community dynamics vary among ulcerative colitis patients after fecal microbiota transplantation. Am J Gastroenterol 2013; 108:1620-1630 [PMID: 24060759 DOI: 10.1038/ajg.2013.257]
41. Aroniadis OC, Brandt LJ. Fecal microbiota transplantation: past, present and future. Curr Opin Gastroenterol 2013; 29: 79-84 [PMID: 23041678 DOI: 10.1097/MOG.0b013e32835a4b3e]
42. Petrof EO, Khoruts A. From stool transplants to next-generation microbiota therapeutics. Gastroenterology 2014; 146: 1573-1582 [PMID: 24412527 DOI: 10.1053/j.gastro.2014.01.004]
43. Ouwehand AC, Salminen S, Isolauri E. Probiotics: an over-view of beneficial effects. Antonie Van Leeuwenhoek 2002; 82: 279-289 [PMID: 12369194]
44. Ianiro G, Bruno G, Lopetuso L, Beghella FB, Laterza L, D' Aversa F, Gigante G, Cammarota G, Gasbarrini A. Role of yeasts in healthy and impaired gut microbiota: the gut my-come. Curr Pharm Des 2014; 20: 4565-4569 [PMID: 24180411]
45. Martins FS, Dalmasso G, Arantes RM, Doye A, Lemichez E, Lagadec P, Imbert V, Peyron JF, Rampai P, Nicoli JR, Czerucka D. Interaction of Saccharomyces boulardii with Salmonella enterica serovar Typhimurium protects mice and modifies T84 cell response to the infection. PLoS One 2010; 5: e8925 [PMID: 20111723 DOI: 10.1371/journal.pone.0008925]
46. Burande MA. Comparison of efficacy of Saccharomyces boulardii strain in the treatment of acute diarrhea in children: A prospective, single-blind, randomized controlled clinical trial. J Pharmacol Pharmacother 2013; 4: 205-208 [PMID: 23960427 DOI: 10.4103/0976-500X.114603]
47. Shan LS, Hou P, Wang ZJ, Liu FR, Chen N, Shu LH, Zhang H, Han XH, Han XX, Cai XX, Shang YX, Vandenplas Y. Prevention and treatment of diarrhoea with Saccharomyces boulardii in children with acute lower respiratory tract infections. Benef Microbes 2013; 4: 329-334 [PMID: 24311316 DOI: 10.3920/BM2013.0008]
48. de Moreno de Leblanc A, Del Carmen S, Zurita-Turk M, Santos Rocha C, van de Guchte M, Azevedo V, Miyoshi A, Leblanc JG. Importance of IL-10 modulation by probiotic microorganisms in gastrointestinal inflammatory diseases. ISRN Gastroenterol 2011; 2011: 892971 [PMID: 21991534 DOI: 10.5402/2011/892971]
49. Isolauri E, Salminen S, Ouwehand AC. Microbial-gut interactions in health and disease. Probiotics. Best Pract Res Clin Gastroenterol 2004; 18: 299-313 [PMID: 15123071 DOI: 10.1016/j.bpg.2003.10.006]
50. Madsen KL, Doyle JS, Jewell LD, Tavernini MM, Fedorak RN. Lactobacillus species prevents colitis in interleukin 10 gene-deficient mice. Gastroenterology 1999; 116: 1107-1114 [PMID: 10220502]
51. O'Mahony L, Feeney M, O'Halloran S, Murphy L, Kiely B, Fitzgibbon J, Lee G, O'Sullivan G, Shanahan F, Collins JK. Probiotic impact on microbial flora, inflammation and tumour development in IL-10 knockout mice. Aliment Pharmacol Ther 2001; 15:1219-1225 [PMID: 11472326]
52. Chaves S, Perdigon G, de Moreno de LeBlanc A. Yoghurt consumption regulates the immune cells implicated in acute intestinal inflammation and prevents the recurrence of the inflammatory process in a mouse model. J Food Prot 2011; 74: 801-811 [PMID: 21549052 DOI: 10.4315/0362-028X. JFP-10-375]
53. Sinagra E, Tomasello G, Cappello F, Leone A, Cottone M, Bellavia M, Rossi F, Facella T, Damiani P, Zeenny MN, Damiani F, Abruzzo A, Damiano G, Palumbo VD, Cocchi M, Jurjus A, Spinelli G, Lo Monte AI, Raimondo D. Probiotics, prebiotics and symbiotics in inflammatory bowel diseases: state-of-the-art and new insights. J Biol Regul Homeost Agents 2013; 27: 919-933 [PMID: 24382173]
54. Ki Cha B, Mun Jung S, Hwan Choi C, Song ID, Woong Lee H, Joon Kim H, Hyuk J, Kyung Chang S, Kim K, Chung WS, Seo JG. The effect of a multispecies probiotic mixture on the symptoms and fecal microbiota in diarrhea-dominant irritable bowel syndrome: a randomized, double-blind, placebocontrolled trial. J Clin Gastroenterol 2012; 46: 220-227 [PMID: 22157240 DOI: 10.1097/MCG.0b013e31823712bl]
55. Persborn M, Gerritsen J, Wallon C, Carlsson A, Akkermans LM, Söderholm JD. The effects of probiotics on barrier function and mucosal pouch microbiota during maintenance treatment for severe pouchitis in patients with ulcerative colitis. Aliment Pharmacol Ther 2013; 38: 772-783 [PMID: 23957603 DOI: 10.1111/apt.12451]
56. Makuuchi M, Takayama T, Kosuge T, Yamazaki S, Yamamoto J, Hasegawa H, Takayasu K. The value of ultrasonography for hepatic surgery. Hepatogastroenterology 1991; 38: 64-70 [PMID: 1851131 DOI: 10.1016/j.anaerobe.2008.04.003]
57. Avalueva EB, UspenskiѤ IuP, Tkachenko EI, Sitkin SI. [Use of Saccharomyces boulardii in treating patients inflammatory bowel diseases (clinical trial)]. Eksp Klin Gastroenterol 2010; (7): 103-111 [PMID: 21033091]
58. Bafutto M, Almeida JR, Leite NV, Costa MB, Oliveira EC, Resende-Filho J. Treatment of diarrhea-predominant irritable bowel syndrome with mesalazine and/or Saccharomyces boulardii. Arq Gastroenterol 2013; 50: 304-309 [PMID: 24474234 DOI: 10.1590/S0004-28032013000400012]
59. Tsai YT, Cheng PC, Pan TM. Anti-obesity effects of gut microbiota are associated with lactic acid bacteria. Appl Microbiol Biotechnol 2014; 98: 1-10 [PMID: 24232731 DOI: 10.1007/ s00253-013-5346-3]
60. da Silva ST, dos Santos CA, Bressan J. Intestinal microbiota; relevance to obesity and modulation by prebiotics and probiotics. Nutr Hosp 2013; 28: 1039-1048 [PMID: 23889619 DOI: 10.3305/nh.2013.28.4.6525]
61. Park DY, Ahn YT, Park SH, Huh CS, Yoo SR, Yu R, Sung MK, McGregor RA, Choi MS. Supplementation of Lactobacillus curvatus HY7601 and Lactobacillus plantarum KY1032 in diet-induced obese mice is associated with gut microbial changes and reduction in obesity. PLoS One 2013; 8: e59470 [PMID: 23555678 DOI: 10.1371/journal.pone.0059470]
62. Yadav H, Lee JH, Lloyd J, Walter P, Rane SG. Beneficial metabolic effects of a probiotic via butyrate-induced GLP-1 hormone secretion, J Biol Chem 2013; 288: 25088-25097 [PMID: 23836895 DOI: 10.1074/jbc.M113.452516]
63. Toral M, Gómez-Guzmán M, Jiménez R, Romero M, Sánchez M, Utrilla MP, Garrido-Mesa N, Rodríguez-Cabezas ME, Olivares M, Gálvez J, Duarte J. The probiotic Lactobacillus coryniformis CECT5711 reduces the vascular pro-oxidant and pro-inflammatory status in obese mice. Clin Sci (Lond) 2014; 127: 33-45 [PMID: 24410749 DOI: 10.1042/cs20130339]
64. Larsen N, Vogensen FK, Gobel RJ, Michaelsen KF, Forssten SD, Lahtinen SJ, Jakobsen M. Effect of Lactobacillus salivarius Ls-33 on fecal microbiota in obese adolescents. Clin Nutr 2013; 32: 935-940 [PMID: 23510724 DOI: 10.1016/ j.clnu.2013.02.007]
65. Lee SJ, Bose S, Seo JG, Chung WS, Lim CY, Kim H. The effects of co-administration of probiotics with herbal medicine on obesity, metabolic endotoxemia and dysbiosis: A randomized double-blind controlled clinical trial. Clin Nutr 2013; Epub ahead of print [PMID: 24411490 DOI: 10.1016/ j.clnu.2013.12.006]
66. Kelishadi R, Farajian S, Mirlohi M. Probiotics as a novel treatment for non-alcoholic Fatty liver disease; a systematic review on the current evidences. Hepat Mon 2013; 13: e7233 [PMID: 23885277 DOI: 10.5812/hepatmon.7233]
67. Ritze Y, Bárdos G, Claus A, Ehrmann V, Bergheim I, Schwiertz A, Bischoff SC. Lactobacillus rhamnosus GG protects against non-alcoholic fatty liver disease in mice. PLoS One 2014; 9: e80169 [PMID: 24475018 DOI: 10.1371/journal. pone.0080169]
68. Ji YS, Kim HN, Park HJ, Lee JE, Yeo SY, Yang JS, Park SY, Yoon HS, Cho GS, Franz CM, Bomba A, Shin HK, Holzapfel WH. Modulation of the murine microbiome with a concomitant anti-obesity effect by Lactobacillus rhamnosus GG and Lactobacillus sakei NR28. Benef Microbes 2012; 3:13-22 [PMID: 22348905 DOI: 10.3920/bm2011.0046]
69. Ebel B, Lemetais G, Beney L, Cachon R, Sokol H, Langella P, Gervais P. Impact of probiotics on risk factors for cardiovascular diseases. A review. Crit Rev Food Sci Nutr 2014; 54: 175-189 [PMID: 24188267 DOI: 10.1080/10408398.2011.57936 1]
70. Taga ME, Walker GC. Pseudo-B12 joins the cofactor family. J Bacteriol 2008; 190:1157-1159 [PMID: 18083805]
71. Tuohy KM, Fava F, Viola R. 'The way to a man's heart is through his gut microbiota'-dietary pro- and prebiotics for the management of cardiovascular risk. Proc Nutr Soc 2014; 73: 172-185 [PMID: 24495527 DOI: 10.1017/s0029665113003911]
72. Cavallini DC, Suzuki JY, Abdalla DS, Vendramini RC, Pauly-Silveira ND, Roselino MN, Pinto RA, Rossi EA. Influence of a probiotic soy product on fecal microbiota and its association with cardiovascular risk factors in an animal model. Lipids Health Dis 2011; 10: 126 [PMID: 21801422 DOI: 10.1186/1476-511X-10-126]
73. Lara-Villoslada F, Sierra S, Boza J, Xaus J, Olivares M. [Ben- eficial effects of consumption of a dairy product containing two probiotic strains, Lactobacillus coryniformis CECT5711 and Lactobacillus gasseri CECT5714 in healthy children]. Nutr Hosp 2007; 22: 496-502 [PMID: 17650892]
74. Ko SJ, Kim J, Han G, Kim SK, Kim HG, Yeo I, Ryu B, Park JW. Laminaria japonica combined with probiotics improves intestinal microbiota: a randomized clinical trial. J Med Food 2014; 17: 76-82 [PMID: 24456357 DOI: 10.1089/jmf.2013.3054]